Annual report pursuant to Section 13 and 15(d)

INCOME TAXES

v3.22.0.1
INCOME TAXES
12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 18 – INCOME TAXES

 

Components of the net loss consist of the following (in thousands):

                 
    Year ended December 31,  
    2021     2020  
Foreign   $ (73,689 )   $ (41,155 )
Domestic     (18,598 )     (9,308 )
Total   $ (92,287 )   $ (50,463 )

 

In 2021, the foreign losses are comprised of $71.9 million related to the Irish operations and $1.8 million related to the Bermudan operations of Tonix International Holding. In 2020, the foreign losses were primarily comprised of $40.4 million related to the Bermudan operations of Tonix International Holding. 

 

A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate used to calculate the Company’s income tax provision is as follows:

                 
    Year Ended December 31,  
    2021     2020  
Statutory federal income tax     (21.0 )%     (21.0 )%
Change in valuation allowance     15.0 %     3.9 %
Foreign loss not subject to income tax     7.0 %     16.9 %
Attribute reduction from control change     (1.2 )%     0.3 %
Other     0.2 %     (0.1 )%
Income Tax Provision     0.0 %     0.0 %

 

 

 

Deferred tax assets (liabilities) and related valuation allowance as of December 31, 2021 and 2020 were as follows (in thousands):

                 
    December 31,  
    2021     2020  
Deferred tax assets/(liabilities):                
Net operating loss carryforward   $ 13,297     $ 2,193  
Stock-based compensation     5,832       3,662  
Other     2,285       220  
Total deferred assets     21,414       6,075  
                 
Valuation allowance     (21,414 )     (6,075 )
                 
Net deferred tax assets   $     $  

 

The Company has incurred research and development (“R&D”) expenses, a portion of which qualifies for tax credits. The Company conducted an R&D credit study to quantify the amount of credits and has claimed an R&D credit on its 2014-2017 tax returns. A portion of these R&D credit carryforwards are subject to annual limitations in their use in accordance with Internal Revenue Service Code (“IRC”) section 383. The R&D credit carryforwards at December 31, 2021 have been reduced to $0.0 million to reflect IRC section 383 ownership changes through December 31, 2021 and the resulting inability to utilize a portion of the R&D credit prior to its expiration.

 

At December 31, 2021, the Company has $66.4 million of Ireland NOL carryforwards that do not expire. At December 31, 2021, the Company has NOL carryforwards of $21.0 million, which do not expire, but their utilization is limited to 80% of taxable income. Additionally, a portion of the federal NOL carryforward is subject to annual limitation in their use in accordance with IRC section 382. As of December 31, 2021, the Company’s Federal NOL carryforwards of $12.9 million have an annual limitation of $2.4 million, and $8.6 million are not subject to limitations. At December 31, 2021, the Company has New Jersey NOL carryforwards of $6.6 million, which expire in 20 years, are subject to annual limitations in their use in accordance with IRC section 382. The New Jersey NOL carryforwards at December 31, 2021 have been reduced to reflect IRC section 382 ownership changes through December 31, 2021 and resultant inability due to annual limitations, to utilize a portion of the NOL prior to its expiration.

 

Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended December 31, 2021. Such objective evidence limits the ability to consider other subjective evidence such as our projections for future growth. As such, the Company has determined that it is not more likely than not that the deferred tax assets will be realized and accordingly, has provided a full valuation allowance against its gross deferred tax assets. The increase in the valuation allowance for the years ended December 31, 2021 and 2020 were $15.3 million, and $2.2 million respectively.

 

The Company recognizes interest accrued related to unrecognized tax benefits and penalties as income tax expense. However, as of December 31, 2021 there are no unrecognized tax benefits recorded. The Company is subject to taxation in the United States and various states and foreign jurisdictions. As of December 31, 2021, the Company’s tax returns remain open and subject to examination by the tax authorities for the tax years 2018 and after.